Antioxidant Drug Lowers Heart Deaths

Novel Drug Targets Underlying Roots of Heart Disease

From the WebMD Archives

March 27, 2007 (New Orleans) -- A novel drug that targets the underlying roots of heart disease can cut the risk of heart attack and stroke and of dying from the disease, a new study suggests.

If the results pan out in future research, "we would have a whole new way of fighting heart disease," says researcher Jean-Claude Tardif, MD, director of research and a professor of medicine at the Montreal Heart Institute in Canada.

The drug, known as succinobucol, "has the potential to change the practice of cardiovascular medicine," he tells WebMD.

Drug Targets Underlying Processes

Current drugs used to prevent heart attacks aim at modifying risk factors -- statins lower cholesterol, for example, while ACE inhibitors control blood pressure, Tardif says.

Succinobucol, on the other hand, has antioxidant and anti-inflammatory properties that target two underlying processes -- oxidative stress and inflammation -- that can play a role in heart disease. (Oxidative stress is where the body essentially has too many free radicals, which are waste products produced by the chemical reactions in the body.)

Oxidative stress and inflammation contribute to the formation of artery-clogging plaque and blood clots that can break off, blocking blood flow to the heart and causing a heart attack, he explains.

Diabetes Risk Slashed, Too

The new study, presented here at the American College of Cardiology’s annual meeting, was designed to see if adding succinobucol to standard drug therapy would reduce heart attacks and death among patients with heart disease.

The researchers studied 6,144 people at high risk of future health problems due to unstable angina (chest pain) or a previous heart attack. Almost all were already taking aspirin as well as statin drugs, ACE inhibitors, and beta-blockers to slow the heart rate and boost the heart's pumping ability.

About half were also given a succinobucol pill once a day and the rest, a placebo.

Over the next two years, those on succinobucol were 19% less likely to die from heart disease, have a heart attack, or die than those on placebo.

Also, only 1.6% of those taking the drug developed diabetes vs. 4.2% on placebo.

Succinobucol was extremely safe, with diarrhea being the most frequent side effect, Tardif says.

Drug to Be Used in Combo

Tardif stresses that the new drug would be given on top of standard heart medications.

The Cleveland Clinic’s E. Murat Tuzcu, MD, chairman of the committee that decided which studies to highlight at the meeting, says there is still more work to be done.

But if the findings are confirmed, succinobucol "will have a big impact in fighting atherosclerosis," he tells WebMD.

WebMD Health News Reviewed by Louise Chang, MD on March 27, 2007


SOURCES: American College of Cardiology 56th Annual Scientific Session, New Orleans, March 24-27, 2007.E. Murat Tuzcu, MD, department of cardiovascular medicine, The Cleveland Clinic. Jean-Claude Tardif, MD, director of research and professor of medicine, Montreal Heart Institute, Canada.

© 2007 WebMD, Inc. All rights reserved.